NZ332690A - Stimulation of host defence mechanisms against viral challenges using interferon - Google Patents

Stimulation of host defence mechanisms against viral challenges using interferon

Info

Publication number
NZ332690A
NZ332690A NZ332690A NZ33269097A NZ332690A NZ 332690 A NZ332690 A NZ 332690A NZ 332690 A NZ332690 A NZ 332690A NZ 33269097 A NZ33269097 A NZ 33269097A NZ 332690 A NZ332690 A NZ 332690A
Authority
NZ
New Zealand
Prior art keywords
interferon
stimulation
against viral
mechanisms against
host defence
Prior art date
Application number
NZ332690A
Other languages
English (en)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of NZ332690A publication Critical patent/NZ332690A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
NZ332690A 1996-05-09 1997-05-05 Stimulation of host defence mechanisms against viral challenges using interferon NZ332690A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
PCT/IB1997/000489 WO1997041883A1 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges

Publications (1)

Publication Number Publication Date
NZ332690A true NZ332690A (en) 2000-07-28

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ332690A NZ332690A (en) 1996-05-09 1997-05-05 Stimulation of host defence mechanisms against viral challenges using interferon
NZ332688A NZ332688A (en) 1996-05-09 1997-05-05 Stimulation of host defence mechanisms against tumors using interferon

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ332688A NZ332688A (en) 1996-05-09 1997-05-05 Stimulation of host defence mechanisms against tumors using interferon

Country Status (17)

Country Link
EP (2) EP0956040B1 (enExample)
JP (2) JP3806446B2 (enExample)
KR (2) KR100399499B1 (enExample)
CN (1) CN1154508C (enExample)
AR (2) AR007058A1 (enExample)
AT (2) ATE316793T1 (enExample)
AU (3) AUPN976596A0 (enExample)
BR (2) BR9709223A (enExample)
CA (2) CA2253902A1 (enExample)
DE (2) DE69735204T2 (enExample)
ES (2) ES2260790T3 (enExample)
ID (2) ID16885A (enExample)
IL (2) IL126970A0 (enExample)
NZ (2) NZ332690A (enExample)
TW (1) TW528599B (enExample)
WO (2) WO1997041883A1 (enExample)
ZA (1) ZA973988B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
DE602005002673T2 (de) 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501236A (enExample) * 1980-08-22 1982-07-15
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
AU9139091A (en) * 1990-12-14 1992-07-08 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
BR9709068A (pt) * 1996-05-09 2000-01-11 Pharma Pacific Pty Ltd Processo de tratamento.

Also Published As

Publication number Publication date
WO1997041886A1 (en) 1997-11-13
EP0898478A4 (en) 1999-05-26
JP2000504027A (ja) 2000-04-04
NZ332688A (en) 2000-07-28
JP3806446B2 (ja) 2006-08-09
DE69735204D1 (de) 2006-04-13
IL126970A0 (en) 1999-09-22
AU724190B2 (en) 2000-09-14
CA2253908A1 (en) 1997-11-13
DE69735201D1 (de) 2006-04-13
BR9709066A (pt) 2000-01-04
AU729514B2 (en) 2001-02-01
AR007058A1 (es) 1999-10-13
JP3806444B2 (ja) 2006-08-09
AR007059A1 (es) 1999-10-13
ZA973988B (en) 1998-11-09
EP0956040B1 (en) 2006-02-01
ES2260794T3 (es) 2006-11-01
KR20000010882A (ko) 2000-02-25
KR20000010880A (ko) 2000-02-25
KR100399501B1 (ko) 2003-12-18
TW528599B (en) 2003-04-21
ID16886A (id) 1997-11-20
CN1154508C (zh) 2004-06-23
AU2399297A (en) 1997-11-26
KR100399499B1 (ko) 2003-12-18
WO1997041883A1 (en) 1997-11-13
JP2000504026A (ja) 2000-04-04
AUPN976596A0 (en) 1996-05-30
IL126972A0 (en) 1999-09-22
ES2260790T3 (es) 2006-11-01
CN1218409A (zh) 1999-06-02
CA2253902A1 (en) 1997-11-13
ATE316791T1 (de) 2006-02-15
EP0898478A1 (en) 1999-03-03
ATE316793T1 (de) 2006-02-15
EP0898478B1 (en) 2006-02-01
EP0956040A1 (en) 1999-11-17
DE69735201T2 (de) 2006-09-21
ID16885A (id) 1997-11-20
DE69735204T2 (de) 2006-09-21
EP0956040A4 (enExample) 1999-11-17
AU2710997A (en) 1997-11-26
BR9709223A (pt) 2000-12-12

Similar Documents

Publication Publication Date Title
TW286283B (enExample)
EP0906119A4 (en) TREATMENT PROCEDURE
ZA944347B (en) The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
WO1987004076A1 (en) Low dosage of interferon to enhance vaccine efficiency
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU2634592A (en) Improved interferon therapy
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
GEP20022672B (en) Pharmaceutical Composition
AU1384995A (en) Human circulating cytokine cc-1
GB9425730D0 (en) Compounds
NZ332688A (en) Stimulation of host defence mechanisms against tumors using interferon
WO2000061176A3 (en) Treatment of multiple sclerosis with a combination of interferon and growth hormone
IL131478A0 (en) Methods for treatment of scar tissue
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
GR3025713T3 (en) Granulocyte colony-stimulating factor solution delivery method.
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
AU7111587A (en) Perhydrothiazepine and perhydroazepine derivatives,their preparation and their therapeutic use
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
ZA979904B (en) Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity.
ITMO910042A1 (it) Vibromassaggiatore per massaggiare il corpo umano.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)